Pulmonary Cell Suspension for Lung Chimerism and Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for lung diseases, such as organ transplantation, are limited by the shortage of organs and the challenge of achieving significant epithelial transdifferentiation and engraftment of stem cells in the complex lung tissue, leading to inadequate repair and regeneration of injured or diseased lungs.
Innovation Solution
Administration of non-syngeneic pulmonary tissue cells in suspension containing hematopoietic precursor cells (HPCs) to induce tolerance and promote lung chimerism without chronic immunosuppressive regimens, using sublethal conditioning protocols and agents like naphthalene to enhance engraftment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-syngeneic pulmonary tissue cells are administered to induce tolerance, then immune tolerance is achieved without chronic immunosuppression, but the complexity of achieving engraftment in complex lung tissue increases
Solution Approach 1:
The pulmonary tissue cells are segmented into specific cell populations, particularly hematopoietic precursor cells (HPCs), which are isolated and administered separately. This segmentation allows for targeted delivery of immunomodulatory cells that can induce tolerance without requiring chronic immunosuppression, thereby resolving the contradiction between achieving reliable immune tolerance and managing transplantation complexity.
Solution Approach 2:
The patent employs preliminary conditioning protocols (such as sublethal conditioning with agents like naphthalene) before administering the pulmonary tissue cells. This preliminary action prepares the host immune system and creates a favorable environment for engraftment, thereby facilitating reliable immune tolerance induction while managing the overall complexity of the transplantation process.
2Reliability
If stem cell based therapies are used for lung repair and regeneration, then potential curative effects are achieved, but the engraftment rate of transplanted cells remains low
Solution Approach 1:
The patent enriches the pulmonary tissue cell suspension for specific cell populations, particularly hematopoietic precursor cells (HPCs), which have demonstrated superior engraftment capabilities. By concentrating these locally-optimized cells with specific functional properties (high engraftment rate), the therapy achieves reliable curative effects while overcoming the general low engraftment rate problem of stem cell therapies in lung tissue.
Solution Approach 2:
The patent utilizes sublethal conditioning protocols that modify physiological parameters (such as using agents like naphthalene) to create a more favorable environment for cell engraftment. These parameter changes in the host system enhance the uptake and survival of transplanted pulmonary tissue cells, thereby increasing the engraftment rate and achieving reliable curative effects.
3Reliability
If organ transplantation is performed to cure end-stage lung disease, then complete lung replacement is achieved, but organ shortage limits availability
Solution Approach 1:
The patent extracts and utilizes specific functional cell populations (hematopoietic precursor cells and other pulmonary tissue cells) from donor organs, separating the therapeutic essence from the entire organ. This extraction approach allows for the delivery of immunomodulatory and regenerative cells without requiring complete organ transplantation, thereby achieving disease cure potential while overcoming organ availability limitations.
Solution Approach 2:
The patent employs pulmonary tissue cells, particularly HPCs, as intermediary agents that mediate between the donor organ and the recipient's immune system. These intermediary cells induce immune tolerance and promote lung repair, providing a middle-ground solution that achieves therapeutic benefits without requiring full organ transplantation, thus addressing both cure reliability and organ availability constraints.
Data Source
AI summary
A method of treating a pulmonary disorder or injury in a subject in need thereof is disclosed. The method comprising administering to the subject non-syngeneic pulmonary tissue cells in suspension comprising an effective amount of hematopoietic precursor cells (HPCs) or supplemented with HPCs, wherein the effective amount is a sufficient amount to achieve tolerance to the pulmonary tissue cells in the absence of chronic immunosuppressive regimen. A method of inducing donor specific tolerance in a subject in need of a pulmonary cell or tissue transplantation is also disclosed.